(Total Views: 525)
Posted On: 05/19/2024 8:40:31 AM
Post# of 148863
In the last week, Merck release data on vicroviroc and mCRC showing no additional benefit to Keytruda. Vicroviroc is a small molecule CCR5 inhibitor similar to Maraviroc that was shelved by Merck about 12 years ago due to lack of efficacy and or side effects in HIV.
The timing of the release of that study and since Merck also owns Keytruda and likely partnered in the MD Anderson animal study with leronlimab is interesting. Dr. Pestell I believe has shown good data with Maraviroc in murine TNBC studies.
Maybe ohm or someone can compare vicroviroc to maraviroc to leronlimab with regards to potential cancer efficacy. The binding with potentially different down stream effects and immune stabilization versus suppression plus side effects.
The timing of the release of that study and since Merck also owns Keytruda and likely partnered in the MD Anderson animal study with leronlimab is interesting. Dr. Pestell I believe has shown good data with Maraviroc in murine TNBC studies.
Maybe ohm or someone can compare vicroviroc to maraviroc to leronlimab with regards to potential cancer efficacy. The binding with potentially different down stream effects and immune stabilization versus suppression plus side effects.
(7)
(0)Scroll down for more posts ▼
